AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06157151
Drug: Pembrolizumab alone
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects randomized will receive IV infusion of pembrolizumab (400 mg) administered every 6 weeks.
Trial: NCT06341764
Drug: Durvalumab 1120 mg
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1120 mg day 1 i.v
Trial: NCT06341764
Drug: Durvalumab 1500 mg
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab i.v. at 1500 mg once every 4 weeks
Trial: NCT06341764
Drug: Tremelimumab i.v. at 300 mg
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT05832255
Drug: Psilocybin, 1.5 mg
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blister packs will contain five capsules of the study drug, Psilocybin 1.5mg. Subjects will be given blister packs with weekly doses at each visit including baseline (day 1), day 8, day 15, day 21, and day 28. Weekly blister packs will contain five doses (1-2 extra capsules depending on the week) to accommodate for flexibility in scheduling. Unused and open packages will be returned to study staff at each visit after baseline.
Trial: NCT05452564
Drug: Baricitinib 2 MG Oral Tablet
RxNorm normalized name: baricitinib 2 MG Oral Tablet
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib, a Janus Kinase inhibitor drug for viral infections, will be administered orally to subjects randomized to this intervention. The dose will be 2 mg orally for ten weeks. This will be compared with placebo intervention. Follow up visits will take place at week 1,2,4 and 10.
Trial: NCT04730583
Drug: Kybella
RxNorm normalized name: Kybella
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection into the cutaneous Neurofibromas lesion
Trial: NCT00006291
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05223920
Drug: Bomedemstat
RxNorm normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (oral)
Trial: NCT04867057
Drug: Trichomylin for SAD
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
Trial: NCT05400265
Drug: HLX26
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
Trial: NCT05400265
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Trial: NCT06419348
Drug: 99mTc-QULIC-5-P1
RxNorm normalized name: ALT-P1
DrugBank: ALT-P1 (DB18485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
Trial: NCT06284902
Drug: Fexofenadine HCl Coated tablet
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet.
Trial: NCT06284902
Drug: Fexofenadine HCl New Formulation Tablet
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: New formulation tablet.
Trial: NCT05254808
Drug: Fosfomycin
RxNorm normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
Trial: NCT05254808
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
Trial: NCT05186285
Drug: CM338
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CM338 : a humanized monoclonal antibody.
Trial: NCT05611749
Drug: Duloxetine 60 MG
RxNorm normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.
Trial: NCT06419335
Drug: CoQ10
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
Trial: NCT03883360
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
Trial: NCT00002008
Drug: Sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05255211
Drug: Remimazolam tosilate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV before procedure
Trial: NCT05255211
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV before procedure
Trial: NCT05096728
Drug: Nifedipine XL
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be enrolled when the primary provider has made the decision to increase the patient's daily dose of Procardia XL from 30mg to 60mg. Participants will be randomized in to one of two groups~* Once daily Nifedipine XL 60mg Vs.~* Twice daily Nifedipine XL 30mg
Trial: NCT04308304
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg and/or 10 mg tablets taken once daily (QD) by mouth.
Trial: NCT05124704
Drug: 5-8ml 0.375% ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
Trial: NCT04551482
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Trial: NCT06681493
Drug: YZJ-4729 Tartrate injection
RxNorm normalized name: metoprolol tartrate Injection
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion, QD
Trial: NCT06681493
Drug: YZJ-4729 simulated injection
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion, QD
Trial: NCT06595121
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 1 mg/2mL nebuliser suspension
Trial: NCT06595121
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort(r) 1 mg/2mL nebuliser suspension
Trial: NCT06681285
Drug: Cadonilimab ;Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab Combined With Anlotinib Followed by Radiotherapy in the Second and Later-line Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Trial: NCT05218668
Drug: Fasudil (WP-0512)
RxNorm normalized name: WP Thyroid
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral fasudil up to 180 mg/day
Trial: NCT05218668
Drug: Fasudil (WP-0512)
RxNorm normalized name: WP Thyroid
DrugBank: Fasudil (DB08162)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral fasudil up to 300 mg/day
Trial: NCT06543836
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg, d1, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Trial: NCT06543836
Drug: Fruquintinib or Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The treatment regimen consists of the following options:~Option 1: Fruquintinib 5mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.~Option 2: Regorafenib 160mg Qd, d1-21, Q4w, and efficacy assessment every 1.5 months.
Trial: NCT06543836
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5mg Qd, d1-14, with a treatment cycle of 21 days, and efficacy assessment every 2 cycles.
Trial: NCT06143735
Drug: Efgbemalenograstim alfa
RxNorm normalized name: efbemalenograstim alfa
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
Trial: NCT05505123
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction and maintenance with sevoflurane for deep sedation
Trial: NCT05505123
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction and maintenance with propofol for deep sedation
Trial: NCT00000842
Drug: Nerve Growth Factor, Recombinant Human
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04444895
Drug: Lanadelumab
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lanadelumab SC injection
Trial: NCT05312372
Drug: Combination (S095033 + paclitaxel)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV)~Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV)
Trial: NCT05049681
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
Trial: NCT05049681
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250mg, q.d.po
Trial: NCT04768075
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody
Trial: NCT04768075
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04768075
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04768075
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV infusion
Trial: NCT04768075
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04768075
Drug: Albumin paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT06231758
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET), a traditional antdiabetic drug, exerts glucose-lowering effect by activating AMPK since it is a critical enzyme in lipid and glucose metabolism
Trial: NCT05447910
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05942300
Drug: CPI-0209
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A second-generation EZH2 inhibitor that has been designed to achieve comprehensive anti-cancer target coverage through extended on-target residence time.
Trial: NCT05942300
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is a chemotherapy drug that contains the metal platinum. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.
Trial: NCT05083780
Drug: Chlorphenesin Carbamate, Hydroxychloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In addition to the mFOLFIRINOX therapy(backbone therapy), chlorphenesin carbamate 250 mg, and hydroxychloroquine 200 mg will be administered orally twice daily for up to 48 weeks.
Trial: NCT05371301
Drug: Paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
Trial: NCT06487416
Drug: Tiotropium Bromide Inhalation Powder
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Trial: NCT05124691
Drug: Albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 400mg single dose
Trial: NCT05709106
Drug: Rimegepant 75 MG
RxNorm normalized name: rimegepant 75 MG
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Trial: NCT06341101
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In case of side effects Perindopril will be replaced by Valsartan
Trial: NCT04996771
Drug: Surufatinib,Etoposide,Cisplatin,Toripalimab
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed.
Trial: NCT04996771
Drug: Surufatinib,Etoposide,Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed.
Trial: NCT05991700
Drug: Freeze-Dried California Table Grape
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Grape (DB10533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Trial: NCT06216886
Drug: Sodium Chloride 0.9% for Injection, Preservative Free
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of saline. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Trial: NCT05446129
Drug: Ezabenlimab
RxNorm normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezabenlimab
Trial: NCT05446129
Drug: BI 765063
RxNorm normalized name: BI-765063
DrugBank: BI-765063 (DB17482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 765063
Trial: NCT05446129
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab
Trial: NCT05049850
Drug: Imlifidase
RxNorm normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly specific for IgG.
Trial: NCT04634799
Drug: TM5614
RxNorm normalized name: TM5614
DrugBank: TM5614 (DB16516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM5614 is provided in 30 mg tablets and 6 tablets (180 mg) will be taken in the evening for up to 7 days.
Trial: NCT03847311
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Trial: NCT06258174
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06096779
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
Trial: NCT06096779
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Trial: NCT06400511
Drug: Pimecrolimus 0.3% Ophthalmic Ointment
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.
Trial: NCT05050149
Drug: PTX-022
RxNorm normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Trial: NCT06557850
Drug: Lu AG22515
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT06033612
Drug: RV299
RxNorm normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Suspension
Trial: NCT06033612
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-filled oral syringe
Trial: NCT06203236
Drug: Furosemide 20 MG
RxNorm normalized name: furosemide 20 MG
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. The median daily total dose of intravenous loop diuretic at the start of treatment will be 20 mg of furosemide.~2. Monitoring of urinary sodium excretion (natriuresis) and diuresis will begin 2 hours after treatment initiation.
Trial: NCT05537896
Drug: Eravacycline
RxNorm normalized name: Eravacycline
DrugBank: Eravacycline (DB12329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eravacycline will be continued until one of the following criteria is met:~* neutrophil recovery (ANC \>500, post-nadir)~* febrile neutropenia~* breakthrough infection~* any grade 3-4 toxicity related to eravacycline use~* 21 days of therapy (maximum duration allowed per study protocol)